Related Experiment Video
Updated: Mar 8, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
The rise and fall of pneumococcal serotypes carried in the PCV era
Vanessa T Devine1, David W Cleary1, Johanna M C Jefferies2
1Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Insights
Pneumococcal conjugate vaccines (PCV) reduced vaccine-type Streptococcus pneumoniae carriage in UK children. Non-vaccine types remained consistent, highlighting the need for ongoing surveillance for new vaccine development.
Area of Science:
- Microbiology
- Immunology
- Public Health
Background:
- Streptococcus pneumoniae causes significant global morbidity and mortality from meningitis, sepsis, and pneumonia.
- Pneumococcal conjugate vaccines (PCV) are crucial for preventing invasive pneumococcal disease (IPD) in children.
- The UK introduced PCV7 in 2006 and PCV13 in 2010, necessitating evaluation of their impact on carriage.
Purpose of the Study:
- To assess pneumococcal carriage rates in young children following PCV implementation in the UK.
- To analyze changes in vaccine-type (VT) and non-vaccine-type (NVT) Streptococcus pneumoniae serotypes.
- To evaluate the long-term impact of PCV7 and PCV13 on nasopharyngeal carriage.
Main Methods:
- Collection of nasopharyngeal swabs from children under five over seven winter seasons (2006-2013).
- Isolation and serotyping of Streptococcus pneumoniae (n=696) from 2267 swabs.
- Statistical analysis to compare serotype prevalence before and after PCV13 introduction.
Main Results:
- A significant decrease in PCV13 vaccine serotypes was observed post-PCV13 introduction (2010/11-2012/13).
- Serotype 6A was the only VT consistently detected post-PCV13; PCV7 serotypes were absent.
- Overall pneumococcal carriage (mean 31.1%) remained consistent, dominated by NVTs, with serotype 15A showing a significant increase (p=0.003).
Conclusions:
- PCVs effectively reduce carriage of targeted VT serotypes through population immunity.
- Increasing IPD attributed to NVTs underscores the need for continuous carriage surveillance.
- Carriage data is vital for informing future vaccine design and public health strategies.
Abstract:
Streptococcus pneumoniae is a major cause of meningitis, sepsis and pneumonia worldwide. Vaccination using pneumococcal conjugate vaccines (PCV) has therefore been part of the UK's childhood immunisation programme since 2006. Here we describe pneumococcal carriage rates in children under five years of age attending the paediatric department of a large UK hospital in response to vaccine implementation over seven winter seasons from 2006 to 2013. S. pneumoniae (n=696) were isolated from nasopharyngeal swabs (n=2267) collected during seven consecutive winters, October to March, 2006/7 to 2012/13. This includes the period immediately following the introduction of the seven-valent pneumococcal conjugate vaccine (PCV7) in 2006 in addition to pre- and post-PCV13 introduction in 2010. We show a decrease in PCV13 vaccine serotypes (VT) in the three years following PCV13 vaccine implementation (2010/11 to 2012/13). Serotype 6A represented the only observed VT following PCV13 implementation with all others (including PCV7 serotypes) absent from carriage. Overall pneumococcal carriage, attributable to non-VT (NVT), was consistent across all sampling years with a mean of 31·1%. The ten most frequently isolated NVTs were 6C, 11A, 15B, 23B, 15A, 21, 22F, 35F, 23A and 15C. Fluctuations in the prevalence of each were however noted. Comparing prevalence at 2006/07 with 2012/13 only 15A was shown to have increased significantly (p value of 0·003) during the course of PCV implementation. These data support the increasing evidence that the primary effect of PCVs is due to population immunity by reducing or eliminating the carriage of invasive VT serotypes. With IPD being increasingly attributed to non-vaccine serotypes, surveillance of carriage data continues to act as an early warning system for vaccine design and public health policy that require continual data of both carried pneumococcal serotypes and IPD attributed serotype data.
More Related Videos
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

